Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseBusiness Wire • 01/04/21
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual MeetingBusiness Wire • 12/07/20
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid TumorsBusiness Wire • 12/07/20
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual MeetingBusiness Wire • 11/15/20
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)Business Wire • 11/12/20
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational ProgressBusiness Wire • 11/09/20
Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020Business Wire • 11/02/20
Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS RatingInvestors Business Daily • 09/16/20
Beyond Mesothelioma, Multiple Sclerosis Could Help Atara’s Stock Soar Exponentially24/7 Wall Street • 09/15/20
Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual CongressBusiness Wire • 09/14/20
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188Business Wire • 09/11/20
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid TumorsBusiness Wire • 09/08/20
Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020Business Wire • 09/01/20
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational ProgressBusiness Wire • 08/05/20
Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings SeasonZacks Investment Research • 08/04/20